The Patent Finder
AP

Acceleron Pharma Inc.

First filing 2005
OverviewNotableFeesChangesFamiliesPatent listSources & methods

135 patents currently held

15 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Nov 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
59
Ending by 2030
Nov 2026
Next term end
51
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
A Method of Increasing Red Blood Cell Levels or Treating Anemia in a Patient US 8,058,229
Cited by 157 later US patents, top 5% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2033.
Ends Nov 2033 · High confidence
Also notable
Variants Derived from Actriib and Uses Therefor US 7,842,663
The most cited patent in this portfolio, cited by 195 later US patents, top 5% of utility patents granted in 2010 in our data. Protection runs to 2028.
Ends Mar 2028 · High confidence
Also notable
Compositions and Methods for Treating Pulmonary Hypertension US 10,722,558
Cited by 23 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2037. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Ends no later than Jul 2037 · Medium confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 4 to 11, 2026 · next Dec 4
  • 3 fees due Jan 23 to 25, 2027 · next Jan 23
  • 1 fee due Feb 13, 2027
    The maintenance fee for Isolated GDF Trap Polypeptide (US 10,377,996) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
  • 3 fees due May 10 to 28, 2027 · next May 10
  • 1 fee due Jun 10, 2027
    The maintenance fee for ALK7 Binding Proteins and Uses Thereof (US 10,501,547) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
  • 1 fee due Jul 2, 2027
    The maintenance fee for Compositions and Methods for Treating Spinal Muscular Atrophy (US 11,857,599) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
  • 1 fee due Aug 4, 2027
    The maintenance fee for Methods for Treating Vascular Eye Disorders with Actrii Antagonists (US 10,550,170) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
  • 2 fees due Nov 7 to 14, 2027 · next Nov 7

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,951,771Activin-Actriia Antagonists and Uses for Promoting Bone Growth
In force
 · Medium confidence
In forceMedium confidence
US 8,067,360A Method for Promoting Bone Growth Using Activin-Actriia Antagonists
In force
 · Medium confidence
In forceMedium confidence
US 8,128,933A Method of Promoting Bone Growth by an Anti-Activin B Antibody
In force
 · High confidence
In forceHigh confidence
US 8,486,403A Method of Promoting Bone Growth by an Anti-Activin a Antibody
In force
 · High confidence
In forceHigh confidence
US 8,629,109Method for Promoting Bone Growth Using Activin-Actriia Antagonists
In force
 · Low confidence
In forceLow confidence
US 9,163,075AN ISOLATED POLYNUCLEOTIDE THAT ENCODES AN ActRIIa-Fc FUSION POLYPEPTIDE
In force
 · Medium confidence
In forceMedium confidence
US 9,480,742Method of Promoting Bone Growth by an Anti-Actriia Antibody
In force
 · High confidence
In forceHigh confidence
US 9,572,865Activin-Actriia Antagonists and Uses for Treating Multiple Myeloma
In force
 · High confidence
In forceHigh confidence
US 10,071,135A Method of Identifying an Agent That Promotes Bone Growth or Increases Bone Density
In force
 · Medium confidence
In forceMedium confidence
US 10,239,940Method of Promoting Bone Growth by an Anti-Actriia Antibody
In force
 · High confidence
In forceHigh confidence
10 of 135 patents shown.
Pro members see all 135.
Pro members: see all 135 patents
Also on record, not counted in the 135: 15 patents in force now held by others · 24 patents ended · 36 applications pending · 116 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited